Clinical Trial Details
Back to clinical trials
Phase IInterventional
An Incremental Dose Escalation Trial of Safety and Tolerability of Curcumin
Protocol: STUDY00007193NCT: NCT06626230
Overview
The purpose of this study is to see if curcumin can reverse anal high-grade squamous intraepithelial lesions (aHSIL) (high-grade anal precancerous cells or high-grade abnormal cells) in people living with HIV to avoid current treatments such as ablation (destroying abnormal cells with heat or surgical excision (cutting out the abnormal cells)), which have potential short- and long-term side effects.
Eligibility
| Ages | 30 Years and older |
| Sex | All |
| Healthy Volunteers | Yes |
| Age Groups | Adult, Older Adult |
Major Inclusion Criteria:
- 30 and older
- Have biopsy-proven anal intraepithelial neoplasia (AIN) 2, AIN 3 without previous treatment
- Or cytology results for ASC-H or HSIL
- Able and willing to complete Study Diary
- Other inclusion criteria apply
Exclusion Criteria:
- Have a clinically significant chronic medical condition that is considered progressive, such as but not limited to coronary disease, congestive heart failure, chronic obstructive lung disease, and diabetes mellitus. Chronic nonprogressive or intermittent syndromes are not excluded, including migraine headaches, mild reactive airway disease, controlled hypertension, stable pain syndromes, or benign gastric reflux.
- Have any history of anal cancer malignancy.
- Pregnant or planning to become pregnant in the next three months.
- Have a history of sensitivity or allergy to any compound used in this study.
- Have Grade 2 or higher renal or hematology abnormality,
- Are currently using, or in the last year have used intravenous drugs (except for therapeutic use), recreational drugs, or alcohol abuse.
- Other exclusion criteria apply
